The impact of peppermint oil on the irritable bowel syndrome: A meta-analysis of the pooled clinical data 11 Medical and Health Sciences 1103 Clinical Sciences

N. Alammar, L. Wang, B. Saberi, J. Nanavati, G. Holtmann, R. T. Shinohara, Gerard Mullin

Research output: Contribution to journalArticle

Abstract

Background: Peppermint oil (PO) has intrinsic properties that may benefit patients with irritable bowel syndrome (IBS) symptoms. The study objective was to determine the effect of peppermint oil in the treatment of the IBS. Methods: We systematically searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane CENTRAL), ClinicalTrials.gov, EMBASE (Ovid), and Web of Science for randomized controlled trials (RCTs) of PO for IBS. We appraised the eligible studies by the Cochrane risk of bias tool. We performed random-effects meta-analysis on primary outcomes including global improvement in IBS symptoms and abdominal pain. A PRISMA-compliant study protocol is registered in PROSPERO Register [2016, CRD42016050917]. Results: Twelve randomized trials with 835 patients were included. For global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of PO (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95% confidence interval (CI): 1.93, 2.97], I 2 = 0%, z = 7.93 (p < 0.00001). Regarding abdominal pain, the RR from six RCTs for the effect of PO (n = 278) versus placebo (n = 278) was 1.78 [95% CI: 1.43, 2.20], I 2 = 0%, z = 5.23 (p < 0.00001). Overall, there were no differences in the reported adverse effects: PO (32 events, 344 total, 9.3%) versus placebo (20 events, 327 total, 6.1%) for eight RCTs; RR 1.40 [95% CI: 0.87, 2.26] I2 = 0%, z = 1.39 (p = 0.16). The number needed to treat with PO to prevent one patient from having persistent symptoms was three for global symptoms and four for abdominal pain. Conclusions: In the most comprehensive meta-analysis to date, PO was shown to be a safe and effective therapy for pain and global symptoms in adults with IBS.

Original languageEnglish (US)
Article number21
JournalBMC Complementary and Alternative Medicine
Volume19
Issue number1
DOIs
StatePublished - Jan 17 2019

Fingerprint

Irritable Bowel Syndrome
Meta-Analysis
Health
Randomized Controlled Trials
Abdominal Pain
Odds Ratio
Placebos
Confidence Intervals
Numbers Needed To Treat
peppermint oil
PubMed
MEDLINE
Pain
Therapeutics

Keywords

  • Abdominal pain
  • Global symptom relief
  • IBS
  • Irritable bowel syndrome
  • Meta-analysis
  • Peppermint oil
  • PRISMA

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

The impact of peppermint oil on the irritable bowel syndrome : A meta-analysis of the pooled clinical data 11 Medical and Health Sciences 1103 Clinical Sciences. / Alammar, N.; Wang, L.; Saberi, B.; Nanavati, J.; Holtmann, G.; Shinohara, R. T.; Mullin, Gerard.

In: BMC Complementary and Alternative Medicine, Vol. 19, No. 1, 21, 17.01.2019.

Research output: Contribution to journalArticle

@article{8d548d72ffac4f749b5fb41d8560284e,
title = "The impact of peppermint oil on the irritable bowel syndrome: A meta-analysis of the pooled clinical data 11 Medical and Health Sciences 1103 Clinical Sciences",
abstract = "Background: Peppermint oil (PO) has intrinsic properties that may benefit patients with irritable bowel syndrome (IBS) symptoms. The study objective was to determine the effect of peppermint oil in the treatment of the IBS. Methods: We systematically searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane CENTRAL), ClinicalTrials.gov, EMBASE (Ovid), and Web of Science for randomized controlled trials (RCTs) of PO for IBS. We appraised the eligible studies by the Cochrane risk of bias tool. We performed random-effects meta-analysis on primary outcomes including global improvement in IBS symptoms and abdominal pain. A PRISMA-compliant study protocol is registered in PROSPERO Register [2016, CRD42016050917]. Results: Twelve randomized trials with 835 patients were included. For global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of PO (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95{\%} confidence interval (CI): 1.93, 2.97], I 2 = 0{\%}, z = 7.93 (p < 0.00001). Regarding abdominal pain, the RR from six RCTs for the effect of PO (n = 278) versus placebo (n = 278) was 1.78 [95{\%} CI: 1.43, 2.20], I 2 = 0{\%}, z = 5.23 (p < 0.00001). Overall, there were no differences in the reported adverse effects: PO (32 events, 344 total, 9.3{\%}) versus placebo (20 events, 327 total, 6.1{\%}) for eight RCTs; RR 1.40 [95{\%} CI: 0.87, 2.26] I2 = 0{\%}, z = 1.39 (p = 0.16). The number needed to treat with PO to prevent one patient from having persistent symptoms was three for global symptoms and four for abdominal pain. Conclusions: In the most comprehensive meta-analysis to date, PO was shown to be a safe and effective therapy for pain and global symptoms in adults with IBS.",
keywords = "Abdominal pain, Global symptom relief, IBS, Irritable bowel syndrome, Meta-analysis, Peppermint oil, PRISMA",
author = "N. Alammar and L. Wang and B. Saberi and J. Nanavati and G. Holtmann and Shinohara, {R. T.} and Gerard Mullin",
year = "2019",
month = "1",
day = "17",
doi = "10.1186/s12906-018-2409-0",
language = "English (US)",
volume = "19",
journal = "BMC Complementary and Alternative Medicine",
issn = "1472-6882",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The impact of peppermint oil on the irritable bowel syndrome

T2 - A meta-analysis of the pooled clinical data 11 Medical and Health Sciences 1103 Clinical Sciences

AU - Alammar, N.

AU - Wang, L.

AU - Saberi, B.

AU - Nanavati, J.

AU - Holtmann, G.

AU - Shinohara, R. T.

AU - Mullin, Gerard

PY - 2019/1/17

Y1 - 2019/1/17

N2 - Background: Peppermint oil (PO) has intrinsic properties that may benefit patients with irritable bowel syndrome (IBS) symptoms. The study objective was to determine the effect of peppermint oil in the treatment of the IBS. Methods: We systematically searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane CENTRAL), ClinicalTrials.gov, EMBASE (Ovid), and Web of Science for randomized controlled trials (RCTs) of PO for IBS. We appraised the eligible studies by the Cochrane risk of bias tool. We performed random-effects meta-analysis on primary outcomes including global improvement in IBS symptoms and abdominal pain. A PRISMA-compliant study protocol is registered in PROSPERO Register [2016, CRD42016050917]. Results: Twelve randomized trials with 835 patients were included. For global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of PO (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95% confidence interval (CI): 1.93, 2.97], I 2 = 0%, z = 7.93 (p < 0.00001). Regarding abdominal pain, the RR from six RCTs for the effect of PO (n = 278) versus placebo (n = 278) was 1.78 [95% CI: 1.43, 2.20], I 2 = 0%, z = 5.23 (p < 0.00001). Overall, there were no differences in the reported adverse effects: PO (32 events, 344 total, 9.3%) versus placebo (20 events, 327 total, 6.1%) for eight RCTs; RR 1.40 [95% CI: 0.87, 2.26] I2 = 0%, z = 1.39 (p = 0.16). The number needed to treat with PO to prevent one patient from having persistent symptoms was three for global symptoms and four for abdominal pain. Conclusions: In the most comprehensive meta-analysis to date, PO was shown to be a safe and effective therapy for pain and global symptoms in adults with IBS.

AB - Background: Peppermint oil (PO) has intrinsic properties that may benefit patients with irritable bowel syndrome (IBS) symptoms. The study objective was to determine the effect of peppermint oil in the treatment of the IBS. Methods: We systematically searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane CENTRAL), ClinicalTrials.gov, EMBASE (Ovid), and Web of Science for randomized controlled trials (RCTs) of PO for IBS. We appraised the eligible studies by the Cochrane risk of bias tool. We performed random-effects meta-analysis on primary outcomes including global improvement in IBS symptoms and abdominal pain. A PRISMA-compliant study protocol is registered in PROSPERO Register [2016, CRD42016050917]. Results: Twelve randomized trials with 835 patients were included. For global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of PO (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95% confidence interval (CI): 1.93, 2.97], I 2 = 0%, z = 7.93 (p < 0.00001). Regarding abdominal pain, the RR from six RCTs for the effect of PO (n = 278) versus placebo (n = 278) was 1.78 [95% CI: 1.43, 2.20], I 2 = 0%, z = 5.23 (p < 0.00001). Overall, there were no differences in the reported adverse effects: PO (32 events, 344 total, 9.3%) versus placebo (20 events, 327 total, 6.1%) for eight RCTs; RR 1.40 [95% CI: 0.87, 2.26] I2 = 0%, z = 1.39 (p = 0.16). The number needed to treat with PO to prevent one patient from having persistent symptoms was three for global symptoms and four for abdominal pain. Conclusions: In the most comprehensive meta-analysis to date, PO was shown to be a safe and effective therapy for pain and global symptoms in adults with IBS.

KW - Abdominal pain

KW - Global symptom relief

KW - IBS

KW - Irritable bowel syndrome

KW - Meta-analysis

KW - Peppermint oil

KW - PRISMA

UR - http://www.scopus.com/inward/record.url?scp=85060182084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060182084&partnerID=8YFLogxK

U2 - 10.1186/s12906-018-2409-0

DO - 10.1186/s12906-018-2409-0

M3 - Article

C2 - 30654773

AN - SCOPUS:85060182084

VL - 19

JO - BMC Complementary and Alternative Medicine

JF - BMC Complementary and Alternative Medicine

SN - 1472-6882

IS - 1

M1 - 21

ER -